Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22472905 | 0.87 | ALDH1A1 (0.53) | HPGDSMN1; SMN2ALDH1A1KMT2ALMNA | |
| SCHEMBL22472933 | 0.84 | HPGD (0.44) | HPGDSMN1; SMN2ALDH1A1KMT2ALMNA | |
| SCHEMBL22472937 | 0.75 | CHRM1 (0.55) | LMNAPOLB | |
| SCHEMBL22472869 | 0.75 | MAPT (0.45) | SMN1; SMN2POLB | |
| SCHEMBL22472880 | 0.75 | MMP13 (0.35) | SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL22472879 | 0.74 | EPHX2 (0.39) | HPGDSMN1; SMN2ALDH1A1KMT2ALMNA | |
| SCHEMBL22472924 | 0.73 | MMP13 (0.36) | SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL21597933 | 0.72 | ALDH1A1 (0.50) | HPGDALDH1A1KMT2ALMNAMEN1 | |
| SCHEMBL22472940 | 0.72 | CYP2C9 (0.41) | ALDH1A1KMT2AMEN1TSHR | |
| SCHEMBL27176073 | 0.69 | HPGD (0.47) | HPGDSMN1; SMN2ALDH1A1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787447-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787447-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | HPGD 2702/4885SMN1; SMN2 2514/4885ALDH1A1 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.